Global Thyroid Gland Disorders Treatment Market Driven by Introduction of Innovative Therapeutic Options

Published on : Mar 09, 2018

Albany, New York, March 9, 2018: Recently, a fresh report on thyroid gland disorder found that the rising incidence rate of thyroid disorders in the North America region is the biggest factor emphasizing the need for effective treatments. Worldwide, thyroid gland disorders such as hypothyroidism, hyperthyroidism, and thyroid nodules affect around 5% to 10% of the population. These factors have resulted in contributing growth factors for global thyroid gland disorder treatment market. Market Research Hub (MRH) has broadcasted this intelligent study titled “Thyroid Gland Disorders Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 – 2025” to its massive online database, which offers major insights, analysis, and valuable guidance on the prospects of global market in the coming years.

This 173-pages study begins with a brief overview of the thyroid gland disorder therapeutic and data analysis of the global market with respect to the segments based on Disorders, and geography. Regions highlighted in the study are Europe, the Asia Pacific excluding Japan, North America, Latin America, Japan and the Middle East and Africa. This subsequent section also showcases the market dynamics and trends such as the drivers, restraints, and opportunities that influence the current nature and future status of this market.

Forecast Assumptions & Key Dynamics

The global thyroid gland disorders treatment market is likely to expand at a steady pace. As per the active research evaluations, the global thyroid gland disorders treatment market was valued worth US$ 1,954.7 Mn in 2016 and is further predicted to reach US$ 2,609.9 Mn by 2025 at a CAGR of 3.3% from 2017 to 2025. Factors such as inactive lifestyle, rising pool of geriatrics, and an increased rate of prevalence of autoimmune diseases such as Grave’s disease and Hashimoto's thyroiditis are largely contributing to the increased patient population for thyroid gland disorders.

Moving further, the research also outlines some of the booming factors in emerging economies, such as the introduction of innovative therapeutic options from leading pharmaceutical companies, increasing awareness among people about the available treatments, and affordability of generic or branded pharmaceutical formulations are also motivating the market.

The research further has been primarily segmented by disorders, which are hypothyroidism and hyperthyroidism. These are further segmented by drug class, such as Levothyroxine and Liothyronine (for hypothyroidism). The hyperthyroidism segment covers drugs such as Propacil and Imidazole.

The final section of the study presents an exhaustive analysis focusing on the prime players operating in the thyroid gland disorder treatment market which are Lanett Company, Inc., Novartis AG, Merck KGaA, Pfizer, Inc., ALLERGAN, Takeda Pharmaceutical Company Limited, Sanofi S.A., AbbVie Inc., Aspen, Mylan N.V., and Others.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top